Cognition Therapeutics gets Nasdaq bid-price deficiency notice; Q3 net loss narrows to $4.1M

COGNITION THERAPEUTICS INC

Nasdaq deficiency letter dated Nov. 3, 2026: CGTX closing bid below $1.00 for 30 consecutive business days; 180 days to May 3, 2027 to regain compliance.
No immediate delisting; shares continue trading on Nasdaq Capital Market. Company may get a second 180-day period and could use a reverse stock split to cure.
Q3 2026 net loss $4.1M, or $(0.04) per share, vs $4.9M, or $(0.06), in Q3 2025; R&D rose to $5.1M from $3.8M.
Cash and restricted cash $31.5M at Sept. 30, 2026, plus $18.2M obligated NIA grant funds; runway estimated into Q4 2027.
FDA aligned on Phase 3 endpoints for zervimesine (CT1812) in dementia with Lewy bodies; Phase 2 START topline expected in 2H 2027.

Featured in Daily 8-K Digest

Selected #5 for 2026-11-05. Read digest

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.